Elizabeth Yurth, M.D.

speaker

572 appearances 1 recordings 1 series first heard Feb 2026 last heard 8 Feb

Elizabeth Yurth, M.D.’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.

Appearances

newest first · ▶ plays the moment

The mindbodygreen Podcast · 636: The ultimate guide to peptides | Elizabeth Yurth, M.D. · 8 Feb 2026 podcast

We were using them for immune health.

and healing.

GLP-1s have gotten a very bad rap because if you put somebody on GLP-1 for weight loss, they stop eating, they stop drinking, they lose muscle mass, they lose bone mass, they lose their hair.

But if you keep somebody on a high protein diet, have them hydrate, that doesn't happen.

GLPs do not cause you to lose muscle at all.

In fact, when they were first developed many years ago, they actually used them because they actually helped put muscle onto their diabetic patients, these little frail diabetics.

So GLP-1s have gotten a bad rap,

And used appropriately, they are a very good drug.

But from a longevity perspective, they're kind of attacking almost everything that we need to attack.

There's GLP-1 receptors on immune cells, so we can bump up immune function.

We know that joints are helped by GLP-1 agonists.

They just published that they failed the trials for the cognitive decline.

But if you read the study, it didn't really fail.

All of their markers got better.

They just probably weren't on them long enough to basically see the substantial change.

So they basically saw, yeah, baselines didn't change in terms of some of their cognitive testing, but their C-reactive proteins went down.

Their immune markers all got better.

Everything got better.

So likely over time,

It's just going to take more time.

Showing 401–420 of 572 · page 21 of 29